These data agreed with the findings described by Sun et al, that reported a higher NK cell-mediated cytolysis of Multiple Myeloma cells dependent on the mAb isatuximab in the presence of the KIR3DL2+, HLA-A3/A11+, and FcγR3A V markers (34). The gene discussed is KIR3DL2; the disease is plasma cell myeloma.